Stephens Investment Management Group LLC decreased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 0.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 590,534 shares of the medical equipment provider’s stock after selling 3,437 shares during the quarter. Stephens Investment Management Group LLC owned about 0.21% of Hologic worth $21,667,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Hall Laurie J Trustee raised its position in Hologic by 10.2% in the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after purchasing an additional 225 shares during the last quarter. Commonwealth Bank of Australia increased its stake in Hologic by 31.0% in the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after buying an additional 600 shares during the period. National Asset Management Inc. acquired a new position in Hologic in the 2nd quarter valued at $203,000. Beck Mack & Oliver LLC acquired a new position in Hologic in the 2nd quarter valued at $209,000. Finally, Notis McConarty Edward acquired a new position in Hologic in the 2nd quarter valued at $213,000. Hedge funds and other institutional investors own 97.72% of the company’s stock.

HOLX has been the topic of several recent research reports. BidaskClub cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Needham & Company LLC reissued a “buy” rating on shares of Hologic in a research note on Tuesday, August 1st. Royal Bank Of Canada dropped their price objective on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) cut shares of Hologic from a “conviction-buy” rating to a “buy” rating and dropped their price objective for the company from $48.00 to $47.00 in a research note on Thursday, August 3rd. Finally, Deutsche Bank AG dropped their price objective on shares of Hologic from $51.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $47.54.

Shares of Hologic, Inc. (HOLX) traded up $0.23 during midday trading on Tuesday, reaching $40.19. 2,200,800 shares of the company were exchanged, compared to its average volume of 2,737,572. The firm has a market cap of $11,519.41, a PE ratio of 19.78, a price-to-earnings-growth ratio of 1.93 and a beta of 0.93. Hologic, Inc. has a 12-month low of $35.76 and a 12-month high of $46.80. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.61 and a current ratio of 0.79.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. The company had revenue of $802.90 million for the quarter, compared to analyst estimates of $792.54 million. Hologic had a net margin of 10.30% and a return on equity of 11.74%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.52 EPS. analysts predict that Hologic, Inc. will post 2.12 earnings per share for the current year.

In other news, VP Karleen Marie Oberton sold 1,256 shares of the stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $39.29, for a total transaction of $49,348.24. Following the transaction, the vice president now directly owns 9,406 shares in the company, valued at approximately $369,561.74. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Elaine Ullian sold 9,282 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,949 shares of company stock worth $1,345,220. 0.79% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “Stephens Investment Management Group LLC Trims Position in Hologic, Inc. (HOLX)” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://theolympiareport.com/2017/11/21/stephens-investment-management-group-llc-trims-position-in-hologic-inc-holx.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.